Akari Therapeutics PLC (NASDAQ:AKTX) — Market Cap & Net Worth
Market Cap & Net Worth: Akari Therapeutics PLC (AKTX)
Akari Therapeutics PLC (NASDAQ:AKTX) has a market capitalization of $7.15 Million ($7.15 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27794 globally and #5658 in its home market, demonstrating a -15.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Akari Therapeutics PLC's stock price $7.86 by its total outstanding shares 1144588 (1.14 Million). Review cash generation quality of Akari Therapeutics PLC to assess how much free cash flow the company generates relative to operating cash flow.
Akari Therapeutics PLC Market Cap History: 2015 to 2026
Akari Therapeutics PLC's market capitalization history from 2015 to 2026. Data shows change from $331.93 Million to $9.00 Million (-30.04% CAGR).
Index Memberships
Akari Therapeutics PLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #798 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2570 of 3165 |
Weight: Akari Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Akari Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Akari Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AKTX by Market Capitalization
Companies near Akari Therapeutics PLC in the global market cap rankings as of August 3, 2026.
Key companies related to Akari Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Akari Therapeutics PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Akari Therapeutics PLC's market cap moved from $331.93 Million to $ 9.00 Million, with a yearly change of -30.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.00 Million | +2619.72% |
| 2025 | $330.79K | -76.31% |
| 2024 | $1.40 Million | -60.90% |
| 2023 | $3.57 Million | -66.80% |
| 2022 | $10.76 Million | -68.67% |
| 2021 | $34.34 Million | -18.92% |
| 2020 | $42.35 Million | +5.71% |
| 2019 | $40.06 Million | +11.46% |
| 2018 | $35.94 Million | -63.74% |
| 2017 | $99.12 Million | -38.49% |
| 2016 | $161.16 Million | -51.45% |
| 2015 | $331.93 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Akari Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.15 Million USD |
| MoneyControl | $7.15 Million USD |
| MarketWatch | $7.15 Million USD |
| marketcap.company | $7.15 Million USD |
| Reuters | $7.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat s… Read more